These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1913229)

  • 21. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
    Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
    Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.
    Dunphy FR; Boyd JH; Kim HJ; Dunphy CH; Harrison BR; Dunleavy TL; Rodriguez JJ; McDonough EM; Minster JR; Hilton JG
    Cancer; 1997 May; 79(10):2016-23. PubMed ID: 9149030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
    Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
    Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.
    Smith JW; Longo DL; Alvord WG; Janik JE; Sharfman WH; Gause BL; Curti BD; Creekmore SP; Holmlund JT; Fenton RG
    N Engl J Med; 1993 Mar; 328(11):756-61. PubMed ID: 8437596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective effect of recombinant human leukemia inhibitory factor against thrombocytopenia in carboplatin-treated mice.
    Akiyama Y; Kikuchi Y; Matsuzaki J; Kajimura N; Ohue C; Yamaguchi K
    Jpn J Cancer Res; 1997 Jun; 88(6):584-9. PubMed ID: 9263536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
    Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Phase I clinical study of combined cisplatin and carboplatin therapy in lung cancer].
    Hayasaka S; Yoshinaga T; Kinuwaki E; Kiyama T; Fujino N
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2011-6. PubMed ID: 1417008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.
    Thiery-Vuillemin A; Dobi E; Nguyen T; Royer B; Montange D; Maurina T; Kalbacher E; Bazan F; Villanueva C; Demarchi M; Chaigneau L; Ivanaj A; Pivot X
    Anticancer Drugs; 2010 Nov; 21(10):958-62. PubMed ID: 20856105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
    Budd GT; Ganapathi R; Bukowski RM; Murthy S
    Eur J Cancer; 1996; 32A Suppl 4():S43-5. PubMed ID: 8976822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of combretastatin a-4 phosphate with carboplatin.
    Bilenker JH; Flaherty KT; Rosen M; Davis L; Gallagher M; Stevenson JP; Sun W; Vaughn D; Giantonio B; Zimmer R; Schnall M; O'Dwyer PJ
    Clin Cancer Res; 2005 Feb; 11(4):1527-33. PubMed ID: 15746056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
    Waterhouse DM; Reynolds RK; Natale RB
    Cancer; 1993 Jun; 71(12):4060-6. PubMed ID: 8508371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trial and pharmacokinetics of carboplatin 560 mg/m2 in children.
    Doz F; Brugières L; Bastian G; Quintana E; Lemerle J; Zucker JM
    Med Pediatr Oncol; 1990; 18(6):459-65. PubMed ID: 2233516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
    Jodrell DI; Egorin MJ; Canetta RM; Langenberg P; Goldbloom EP; Burroughs JN; Goodlow JL; Tan S; Wiltshaw E
    J Clin Oncol; 1992 Apr; 10(4):520-8. PubMed ID: 1548516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin.
    Edmonson JH; Hartmann LC; Long HJ; Colon-Otero G; Fitch TR; Jefferies JA; Braich TA; Maples WJ
    Cancer; 1992 Nov; 70(10):2529-39. PubMed ID: 1423182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
    Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study.
    Kudoh S; Sawa T; Kurihara N; Furuse K; Kurita Y; Fukuoka M; Takada M; Takaku F; Ogawa M; Ariyoshi Y
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S89-95. PubMed ID: 8765425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carboplatin-based combination chemotherapy for testicular cancer: relationship among administration dose of carboplatin, renal function and myelosuppression.
    Suzuki K; Matsumoto K; Hashimoto K; Kurokawa K; Jinbo S; Suzuki T; Imai K; Yamanaka H; Kawashima K; Takahashi H
    Hinyokika Kiyo; 1995 Oct; 41(10):775-80. PubMed ID: 8533673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infusional carboplatin. Phase I studies of 5-day and 14-day infusions.
    Lokich J; Anderson N; Bern M; Zipli T; Gonsalves L; Moore C
    Cancer; 1991 Jul; 68(1):68-71. PubMed ID: 2049755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.